Cognitive function in schizophrenia: Conflicting findings and future directions

Reviews in the Neurosciences

Volumn 27, Issue 4, 2016, Pages 435-448

  Moustafa, Ahmed A ^a,b   Garami, Julia K ^c   Mahlberg, Justin ^a   Golembieski, Jan ^d   Keri, Szabolcs ^e   Misiak, Blazej ^f   Frydecka, Dorota ^f  

^a UNIVERSITY OF WESTERN SYDNEY   (Australia)

^b WESTERN SYDNEY UNIVERSITY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^e NATIONAL INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Hungary)

^f WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

attention; cognition; dopamine; learning; schizophrenia; working memory

Indexed keywords

DOPAMINE; NEUROLEPTIC AGENT;

ARTICLE; ATTENTION; AUDITORY MASKING; AUDITORY STIMULATION; COGNITION; COGNITIVE DEFECT; HUMAN; LATENT INHIBITION; LEARNING; NEGATIVE SYNDROME; POSITIVE SYNDROME; PRIORITY JOURNAL; SCHIZOPHRENIA; SELECTIVE ATTENTION; SHORT TERM MEMORY; WORKING MEMORY; ANIMAL; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY;

ANIMALS; ANTIPSYCHOTIC AGENTS; ATTENTION; COGNITION; COGNITION DISORDERS; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84974588027     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/revneuro-2015-0060     Document Type: Article

References (204)

1. Abi-Dargham, A. (2003). Probing cortical dopamine function in schizophrenia: what can D1 receptors tell us? World Psychiatry 2, 166-171.
2. Abi-Dargham, A., Mawlawi, O., Lombardo, I., Gil, R., Martinez, D., Huang, Y., Hwang, D.-R., Keilp, J., Kochan, L., Van Heertum, R., et al. (2002). Prefrontal dopamine D1 receptors and working memory in schizophrenia. J. Neurosci. 22, 3708-3719.
3. Akil, M., Pierri, J.N., Whitehead, R.E., Edgar, C.L., Mohila, C., Sampson, A.R., and Lewis, D.A. (1999). Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am. J. Psychiatry 156, 1580-1589.
4. Asenjo Lobos, C., Komossa, K., Rummel-Kluge, C., Hunger, H., Schmid, F., Schwarz, S., and Leucht, S. (2010). Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. 10. Available at: http://www. ncbi.nlm.nih.gov/pubmed/21069690.
5. Baddeley, A. (1981). The concept of working memory: a view of its current state and probable future development. Cognition 10, 17-23.
6. Barch, D.M., Carter, C.S., Braver, T.S., Sabb, F.W., MacDonald, A., 3rd, Noll, D.C., and Cohen, J.D. (2001). Selective deficits in prefrontal cortex function in medication-naive patients with schizophrenia. Arch. Gen. Psychiatry 58, 280-288.
7. Barch, D.M., Mitropoulou, V., Harvey, P.D., New, A.S., Silverman, J.M., and Siever, L.J. (2004). Context-processing deficits in schizotypal personality disorder. J. Abnorm. Psychol. 113, 556-568.
8. Baruch, I., Hemsley, D.R., and Gray, J.A. (1988). Differential performance of acute and chronic schizophrenics in a latent inhibition task. J. Nerv. Ment. Dis. 176, 598-606.
9. Becker, A., Peters, B., Schroeder, H., Mann, T., Huether, G., and Grecksch, G. (2003). Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 27, 687-700.
10. Bedard, M.A., Scherer, H., Stip, E., Cohen, H., Rodriguez, J.P., and Richer, F. (2000). Procedural learning in schizophrenia: further consideration on the deleterious effect of neuroleptics. Brain Cogn. 43, 31-39.
11. Beninger, R.J. (2006). Dopamine and incentive learning: a framework for considering antipsychotic medication effects. Neurotox. Res. 10, 199-209.
12. Bilder, R.M., Volavka, J., Czobor, P., Malhotra, A.K., Kennedy, J.L., Ni, X., Lindenmayer, J.P., Citrome. L., McEvoy. J., Kunz, M., et al. (2002a). Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol. Psychiatry 52, 701-707.
13. Bilder, R.M., Goldman, R.S., Volavka, J., Czobor, P., Hoptman, M., Sheitman, B., Goldman, R.S., Hoptman, M.J., Sheitman, B., Lindenmayer, J.P. et al. (2002b). Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am. J. Psychiatry 159, 1018-1028.
14. Bodi, N., Csibri, E., Myers, C.E., Gluck, M.A., and Keri, S. (2009). Associative learning, acquired equivalence, and flexible generalization of knowledge in mild Alzheimer disease. Cogn. Behav. Neurol. 22, 89-94.
15. Bogerts, B., Meertz, E., and Schonfeldt-Bausch, R. (1985). Basal ganglia and limbic system pathology in schizophrenia. A morphometric study of brain volume and shrinkage. Arch. Gen. Psychiatry 42, 784-791.
16. Bondolfi, G., Dufour, H., Patris, M., May, J.P., Billeter, U., Eap, C.B., and Baumann, P. (1998). Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am. J. Psychiatry 155, 499-504.
17. Bora, E. and Murray, R.M. (2014). Meta-analysis of cognitive deficits in ultra-high risk to psychosis and first-episode psychosis: do the cognitive deficits progress over, or after, the onset of psychosis? Schizophr. Bull. 40, 744-755.
18. Bourque, J., Lakis, N., Champagne, J., Stip, E., Lalonde, P., Lipp, O., and Mendrek, A. (2013). Clozapine and visuospatial processing in treatment-resistant schizophrenia. Cogn. Neuropsychiatry 18, 615-630.
19. Brahmbhatt, S.B., Haut, K., Csernansky, J.G., and Barch, D.M. (2006). Neural correlates of verbal and nonverbal working memory deficits in individuals with schizophrenia and their high-risk siblings. Schizophr. Res. 87, 191-204.
20. Breier, A.F., Malhotra, A.K., Su, T.P., Pinals, D.A., Elman, I., Adler, C.M., Lafargue, R.T., Clifton, A., and Pickar, D. (1999). Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am. J. Psychiatry 156, 294-298.
21. Buckley, P.F. and Stahl, S.M. (2007). Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac? Acta Psychiatr. Scand. 115, 93-100.
22. Burch, G.S., Hemsley, D.R., and Joseph, M.H. (2004). Trials-to-criterion latent inhibition in humans as a function of stimulus pre-exposure and positive-schizotypy. Br. J. Psychol. 95(Pt 2), 179-196.
23. Buschman, T.J. and Miller, E.K. (2007). Top-down versus bottom-up control of attention in the prefrontal and posterior parietal cortices. Science 315, 1860-1862.
24. Carlsson, A., Waters, N., Holm-Waters, S., Tedroff, J., Nilsson, M., and Carlsson, M.L. (2001). Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu. Rev. Pharmacol. Toxicol. 41, 237-260.
25. Carpenter, W.T., Jr., Heinrichs, D.W., and Wagman, A.M. (1988). Deficit and nondeficit forms of schizophrenia: the concept. Am. J. Psychiatry 145, 578-583.
26. Castner, S.A., Williams, G.V., and Goldman-Rakic, P.S. (2000). Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science 287, 2020-2022.
27. Chapman, L.J. and Chapman, J.P. (1973). Problems in the measurement of cognitive deficit. Psychol. Bull. 79, 380-385.
28. Clark, A. (2013). Whatever next? predictive brains, situated agents, and the future of cognitive science. Behav. Brain Sci. 36, 181-204.
29. Cohen, J.D., Barch, D.M., Carter, C., and Servan-Schreiber, D. (1999). Context-processing deficits in schizophrenia: converging evidence from three theoretically motivated cognitive tasks. J. Abnorm. Psychol. 108, 120-133.
30. Cohen, J.D., Braver, T.S., and Brown, J.W. (2002). Computational perspectives on dopamine function in prefrontal cortex. Curr. Opin. Neurobiol. 12, 223-229.
31. Collerton, D., Perry, E., and McKeith, I. (2005). Why people see things that are not there: a novel Perception and Attention Deficit model for recurrent complex visual hallucinations. Behav. Brain Sci. 28, 737-757; discussion 757-794.
32. Collins, A.G., Brown, J.K., Gold, J.M., Waltz, J.A., and Frank, M.J. (2014). Working memory contributions to reinforcement learning impairments in schizophrenia. J. Neurosci. 34, 13747-13756.
33. Corlett, P.R., Honey, G.D., and Fletcher, P.C. (2007). From prediction error to psychosis: ketamine as a pharmacological model of delusions. J. Psychopharmacol. 21, 238-252.
34. Coull, J.T. (2005). Psychopharmacology of human attention. In: Neurobiology of Attention (e-publication). L. Itti, G. Rees and J.K. Tsotsos, eds. (New York, NY: Elsevier Inc./Academic Press). pp. 50-56.
35. Curtis, V.A., Katsafouros, K., Moller, H.J., Medori, R., and Sacchetti, E. (2008). Long-acting risperidone improves negative symptoms in stable psychotic patients. J. Psychophar-macol. 22, 254-261.
36. D'Ardenne, K., McClure, S.M., Nystrom, L.E., and Cohen, J.D. (2008). BOLD responses reflecting dopaminergic signals in the human ventral tegmental area. Science 319, 1264-1267.
37. Dassa, D., Naudin, J., and Azorin, J.M. (1995). [New neuroleptic agents and new models for psychoses]. Ann. Med. Psychol. (Paris) 153, 106-120.
38. Davis, K.L., Kahn, R.S., Ko, G., and Davidson, M. (1991). Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 148, 1474-1486.
39. de Bartolomeis, A., Balletta, R., Giordano, S., Filomena Buonaguro, E., Latte, G., and Lasevoli, F. (2013). Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psycho-pathology, attitude to the treatment and antipsychotics doses. Psychiatry Res. 210, 387-395.
40. DeRosse, P., Hodgkinson, C.A., Lencz, T., Burdick, K.E., Kane, J.M., Goldman, D., and Malhotra, A.K. (2007). Disrupted in schizophrenia 1 genotype and positive symptoms in schizophrenia. Biol. Psychiatry 61, 1208-1210.
41. Deserno, L., Boehme, R., Heinz, A., and Schlagenhauf, F. (2013). Reinforcement learning and dopamine in schizophrenia: dimensions of symptoms or specific features of a disease group? Front Psychiatry 4, 172.
42. Diwadkar, V.A., Goradia, D., Hosanagar, A., Mermon, D., Montrose, D.M., Birmaher, B., Axelson, D., Rajarathinem, R., Haddad, L., Amirsadri, A., et al. (2011). Working memory and attention deficits in adolescent offspring of schizophrenia or bipolar patients: comparing vulnerability markers. Prog. Neuropsychopharmacol. Biol. Psychiatry 35, 1349-1354.
43. Dunn, L.A., Atwater, G.E., and Kilts, C.D. (1993). Effects of anti-psychotic drugs on latent inhibition: sensitivity and specificity of an animal behavioral model of clinical drug action. Psychopharmacology (Berl) 112, 315-323.
44. Eich, T.S., Nee, D.E., Insel, C., Malapani, C., and Smith, E.E. (2014). Neural correlates of impaired cognitive control over working memory in schizophrenia. Biol. Psychiatry 76, 146-153.
45. Elvevag, B. and Goldberg, T.E. (2000). Cognitive impairment in schizophrenia is the core of the disorder. Crit. Rev. Neurobiol. 14, 1-21.
46. Evans, L.H., Gray, N.S., and Snowden, R.J. (2007). A new continuous within-participants latent inhibition task: examining associations with schizotypy dimensions, smoking status and gender. Biol. Psychol. 74, 365-373.
47. Farde, L., Wiesel, F.A., Halldin, C., and Sedvall, G. (1988). Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch. Gen. Psychiatry 45, 71-76.
48. Farkas, M., Polgar, P., Kelemen, O., Rethelyi, J., Bitter, I., Myers, C.E., Gluck, M.A., and Kéri, S. (2008). Associative learning in deficit and nondeficit schizophrenia. Neuroreport 19, 55-58.
49. Fatouros-Bergman, H., Cervenka, S., Flyckt, L., Edman, G., and Farde, L. (2014). Meta-analysis of cognitive performance in drug-naive patients with schizophrenia. Schizophr. Res. 158, 156-162.
50. Feldon, J. and Weiner, I. (1991). The latent inhibition model of schizophrenic attention disorder. Haloperidol and sulpiride enhance rats' ability to ignore irrelevant stimuli. Biol. Psychiatry 29, 635-646.
51. Fervaha, G., Agid, O., Foussias, G., and Remington, G. (2013). Impairments in both reward and punishment guided reinforcement learning in schizophrenia. Schizophr. Res. 150, 592-593.
52. Fink-Jensen, A. (2000). Novel pharmacological approaches to the treatment of schizophrenia. Dan. Med. Bull. 47, 151-167.
53. Fiorillo, C.D. (2011). Transient activation of midbrain dopamine neurons by reward risk. Neuroscience 197, 162-171.
54. Fiorillo, C.D., Tobler, P.N., and Schultz, W. (2003). Discrete coding of reward probability and uncertainty by dopamine neurons. Science 299, 1898-1902.
55. Fitton, A. and Heel, R.C. (1990). Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 40, 722-747.
56. Fletcher, P.C. and Frith, C.D. (2009). Perceiving is believing: a Bayesian approach to explaining the positive symptoms of schizophrenia. Nat. Rev. Neurosci 10, 48-58.
57. Foerde, K., Poldrack, R.A., Khan, B.J., Sabb, F.W., Bookheimer, S.Y., Bilder, R.M., Guthrie, D., Granholm, E., Nuechterlein, K.H., Marder, S.R., et al. (2008). Selective corticostriatal dysfunction in schizophrenia: examination of motor and cognitive skill learning. Neuropsychology 22, 100-109.
58. Forbes, N.F., Carrick, L.A., McIntosh, A.M., and Lawrie, S.M. (2009). Working memory in schizophrenia: a meta-analysis. Psychol. Med. 39, 889-905.
59. Friston, K. (2003). Learning and inference in the brain. Neural Networks 16, 1325-1352.
60. Frith, C.D. (1979). Consciousness, information processing and schizophrenia. Br. J. Psychiatry 134, 225-235.
61. Frith, C.D. and Done, D.J. (1988). Towards a neuropsychology of schizophrenia. Br. J. Psychiatry 153, 437-443.
62. Frith, C.D. and Done, D.J. (1989). Experiences of alien control in schizophrenia reflect a disorder in the central monitoring of action. Psychol. Med. 19, 359-363.
63. Frydecka, D., Eissa, A.M., Hewedi, D.H., Ali, M., Drapala, J., Misiak, B., Klosinska, E., Phillips, J.R., and Moustafa, A.A. (2014). Impairments of working memory in schizophrenia and bipolar disorder: the effect of history of psychotic symptoms and different aspects of cognitive task demands. Front. Behav. Neurosci. 8, 416.
64. Fujimaki, K., Takahashi, T., and Morinobu, S. (2012). Association of typical versus atypical antipsychotics with symptoms and quality of life in schizophrenia. PLoS One 7, e37087.
65. Glahn, D.C., Ragland, J.D., Abramoff, A., Barrett, J., Laird, A.R., Bearden, C.E., and Velligan, D.I. (2005). Beyond hypofrontality: a quantitative meta-analysis of functional neuroimaging studies of working memory in schizophrenia. Hum. Brain. Mapp. 25, 60-69.
66. Gold, J.M., Fuller, R.L., Robinson, B.M., McMahon, R.P., Braun, E.L., and Luck, S.J. (2006). Intact attentional control of working memory encoding in schizophrenia. J. Abnorm. Psychol. 115, 658-673.
67. Goldman-Rakic, P.S. (1994). Working memory dysfunction in schizophrenia. J. Neuropsychiatry Clin. Neurosci. 6, 348-357.
68. Goldman-Rakic, P.S., Castner, S.A., Svensson, T.H., Siever, L.J., and Williams, G.V. (2004). Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl) 174, 3-16.
69. Goldman, M.B. and Mitchell, C.P. (2004). What is the functional significance of hippocampal pathology in schizophrenia? Schizophr. Bull. 30, 367-392.
70. Golembiewski, J. (2013). The subcortical confinement hypothesis for schizotypal hallucinations. Cureus 5, e118.
71. Gouzoulis-Mayfrank, E., Heekeren, K., Voss, T., Moerth, D., Thelen, B., and Meincke, U. (2004). Blunted inhibition of return in schizophrenia-evidence from a longitudinal study. Prog Neuropsychopharmacol. Biol. Psychiatry 28, 389-396.
72. Gouzoulis-Mayfrank, E., Balke, M., Hajsamou, S., Ruhrmann, S., Schultze-Lutter, F., Daumann, J., and Heekeren, K. (2007). Orienting of attention in unmedicated patients with schizophrenia, prodromal subjects and healthy relatives. Schizophr. Res. 97, 35-42.
73. Grace, A.A. (2010). Dopamine system dysregulation by the ventral subiculum as the common pathophysiological basis for schizophrenia psychosis, psychostimulant abuse, and stress. Neurotox. Res. 18, 367-376.
74. Gray, J.A., Feldon, J., Rawlins, J.N.P., Hemsley, D.R., and Smith, A.D. (1991a). The neuropsychology of schizophrenia. Behav. Brain Sci. 14, 1-20.
75. Gray, J.A., Feldon, J., Rawlins, J.N.P., Hemsley, D., and Smith, A.D. (1991b). The neurophysiology of schizophrenia. Behav. Brain Sci. 14, 1-84.
76. Gray, N.S., Pickering, A.D., Hemsley, D.R., Dawling, S., and Gray, J.A. (1992). Abolition of latent inhibition by a single 5 mg dose of d-amphetamine in man. Psychopharmacology (Berl) 107, 425-430.
77. Gray, N.S., Fernandez, M., Williams, J., Ruddle, R.A., and Snowden, R.J. (2002). Which schizotypal dimensions abolish latent inhibition? Br. J. Clin. Psychol. 41(Pt 3), 271-284.
78. Guillin, O., Abi-Dargham, A., and Laruelle, M. (2007). Neurobiology of dopamine in schizophrenia. Int. Rev. Neurobiol. 78, 1-39.
79. Harris, M.S., Wiseman, C.L., Reilly, J.L., Keshavan, M.S., and Sweeney, J.A. (2009). Effects of risperidone on procedural learning in antipsychotic-naive first-episode schizophrenia. Neuropsychopharmacology 34, 468-476.
80. Hazy, T.E., Frank, M.J., and O'Reilly R.C. (2007). Towards an executive without a homunculus: computational models of the prefrontal cortex/basal ganglia system. Philos. Trans. R. Soc. Lond. B Biol. Sci. 362, 1601-1613.
81. Heckers, S., Goff, D., Schacter, D.L., Savage, C.R., Fischman, A.J., Alpert, N.M., and Rauch, S.L. (1999). Functional imaging of memory retrieval in deficit vs nondeficit schizophrenia. Arch. Gen. Psychiatry 56, 1117-1123.
82. Heinz, A. and Schlagenhauf, F. (2010). Dopaminergic dysfunction in schizophrenia: salience attribution revisited. Schizophr. Bull. 36, 472-485.
83. Hill, S.K., Reilly, J.L., Keefe, R.S., Gold, J.M., Bishop, J.R., Gershon, E.S., Tamminga, C.A., Pearlson, G.D., Keshavan, M.S., and Sweeney, J.A. (2013). Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. Am. J. Psychiatry 170, 1275-1284.
84. Ho, B.C., Andreasen, N.C., Ziebell, S., Pierson, R., and Magnotta, V. (2011). Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch. Gen. Psychiatry 68, 128-137.
85. Holmes, A.J., MacDonald, A., 3rd, Carter, C.S., Barch, D.M., Andrew Stenger, V., and Cohen, J.D. (2005). Prefrontal functioning during context processing in schizophrenia and major depression: an event-related fMRI study. Schizophr. Res. 76, 199-206.
86. Horacek, J., Bubenikova-Valesova, V., Kopecek, M., Palenicek, T., Dockery, C., Mohr, P., and Höschl, C. (2006). Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 20, 389-409.
87. Howes, O.D. and Kapur, S. (2009). The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizo-phr. Bull. 35, 549-562.
88. Javitt, D.C. (2009). Sensory processing in schizophrenia: neither simple nor intact. Schizophr. Bull. 35, 1059-1064.
89. Javitt, D.C., Shelley, A.M., Silipo, G., and Lieberman, J.A. (2000). Deficits in auditory and visual context-dependent processing in schizophrenia: defining the pattern. Arch. Gen. Psychiatry 57, 1131-1137.
90. Jones, H.M. (2004). On biology, phenomenology, and pharmacology in schizophrenia. Am. J. Psychiatry 161, 376-377; author reply 377-378.
91. Joseph, M.H., Frith, C.D., and Waddington, J.L. (1979). Dopaminergic mechanisms and cognitive deficit in schizophrenia. A neuro-biological model. Psychopharmacology (Berl) 63, 273-280.
92. Juckel, G., Schlagenhauf, F., Koslowski, M., Filonov, D., Wustenberg, T., Villringer, A., Knutson, B., Kienast, T., Gallinat. J., Wrase. J., et al. (2006). Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology (Berl) 187, 222-228.
93. Kane, J., Honigfeld, G., Singer, J., and Meltzer, H. (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45, 789-796.
94. Kapur, S. (2003). Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am. J. Psychiatry 160, 13-23.
95. Kapur, S., Mizrahi, R., and Li, M. (2005). From dopamine to salience to psychosis-linking biology, pharmacology and phenomenology of psychosis. Schizophr. Res. 79, 59-68.
96. Kathmann, N., von Recum, S., Haag, C., and Engel, R.R. (2000). Electrophysiological evidence for reduced latent inhibition in schizophrenic patients. Schizophr. Res. 45, 103-114.
97. Keedy, S.K., Reilly, J.L., Bishop, J.R., Weiden, P.J., and Sweeney, J.A. (2015). Impact of Antipsychotic treatment on attention and motor learning systems in first-episode schizophrenia. Schizophr. Bull. 41, 355-365.
98. Keefe, R.S. and Fenton, W.S. (2007). How should DSM-V criteria for schizophrenia include cognitive impairment? Schizophr. Bull. 33, 912-920.
99. Keefe, R.S., Silva, S.G., Perkins, D.O., and Lieberman, J.A. (1999). The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr. Bull. 25, 201-222.
100. Keefe, R.S., Bilder, R.M., Davis, S.M., Harvey, P.D., Palmer, B.W., Gold, J.M., Meltzer, H.Y., Green, M.F., Capuano, G., Stroup, T.S., et al. (2007a). Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 64, 633-647.
101. Keefe, R.S., Sweeney, J.A., Gu, H., Hamer, R.M., Perkins, D.O., McEvoy, J.P., and Lieberman, J.A. (2007b). Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am. J. Psychiatry 164, 1061-1071.
102. 18F]fallypride positron emission tomography. Biol. Psychiatry 68, 634-641.
103. Kempton, M.J., Stahl, D., Williams, S.C., and DeLisi, L.E. (2010). Progressive lateral ventricular enlargement in schizophrenia: a meta-analysis of longitudinal MRI studies. Schizophr. Res. 120, 54-62.
104. Keri, S. (2008). Interactive memory systems and category learning in schizophrenia. Neurosci. Biobehav. Rev. 32, 206-218.
105. Kessler, R.M., Woodward, N.D., Riccardi, P., Li, R., Ansari, M.S., Anderson, S., Dawant, B., Zald, D., and Meltzer, H.Y. (2009). Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biol. Psychiatry 65, 1024-1031.
106. 123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics. Am. J. Psychiatry 153, 183-190.
107. Koch, K., Schachtzabel, C., Wagner, G., Schikora, J., Schultz, C., Reichenbach, J.R., Sauer, H., and Schlösser, R.G. (2010). Altered activation in association with reward-related trial-and-error learning in patients with schizophrenia. Neuroimage 50, 223-232.
108. Konopaske, G.T., Dorph-Petersen, K.A., Sweet, R.A., Pierri, J.N., Zhang, W., Sampson, A.R., and Lewis, D.A. (2008). Effect of chronic antipsychotic exposure on astrocyte and oligoden-drocyte numbers in macaque monkeys. Biol. Psychiatry 63, 759-765.
109. Krieckhaus, E.E., Donahoe, J.W., and Morgan, M.A. (1992). Paranoid schizophrenia may be caused by dopamine hyperactivity of CA1 hippocampus. Biol. Psychiatry 31, 560-570.
110. Laruelle, M. and Abi Dargham, A. (1999). Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J. Psychopharmacol. 13, 358-371.
111. Laruelle, M., Abi-Dargham, A., Gil, R., Kegeles, L., and Innis, R. (1999). Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol. Psychiatry 46, 56-72.
112. Lee, J. and Park, S. (2005). Working memory impairments in schizophrenia: a meta-analysis. J. Abnorm. Psychol. 114, 599-611.
113. Lee, J. and Park, S. (2006). The role of stimulus salience in CPT-AX performance of schizophrenia patients. Schizophr. Res. 81, 191-197.
114. Leysen, J.E., Gommeren, W., Eens, A., de Chaffoy de Courcelles, D., Stoof, J.C., and Janssen, P.A. (1988). Biochemical profile of risperidone, a new antipsychotic. J. Pharmacol. Exp. Ther. 247, 661-670.
115. Lubow, R.E. (1973). Latent inhibition. Psychol. Bull. 79, 398-407.
116. Lubow, R.E. (1989). Latent Inhibition and Conditioned Attention Theory. (Cambridge, UK: Cambridge University Press).
117. Lubow, R.E. (1992). Latent inhibition in low and high "psychotic-prone" normal subjects. Pers. Indiv. Differ. 13, 563-572.
118. Lubow, R.E., Kaplan, O., Abramovich, P., Rudnick, A., and Laor, N. (2000). Visual search in schizophrenia: latent inhibition and novel pop-out effects. Schizophr. Res. 45, 145-156.
119. Luck, S.J. and Gold, J.M. (2008). The construct of attention in schizophrenia. Biol. Psychiatry 64, 34-39.
120. Lynch, M.R. (1992). Schizophrenia and the D1 receptor: focus on negative symptoms. Prog. Neuropsychopharmacol. Biol. Psychiatry 16, 797-832.
121. MacDonald, A.W., Pogue-Geile, M.F., Johnson, M.K., and Carter, C.S. (2003). A specific deficit in context processing in the unaffected siblings of patients with schizophrenia. Arch. Gen. Psychiatry 60, 57-65.
122. MacDonald, P.A., MacDonald, A.A., Seergobin, K.N., Tamjeedi, R., Ganjavi, H., Provost, J.S., and Monchi, O. (2011). The effect of dopamine therapy on ventral and dorsal striatum-mediated cognition in Parkinson's disease: support from functional MRI. Brain 134(Pt 5), 1447-1463.
123. Malhotra, A.K., Kestler, L.J., Mazzanti, C., Bates, J.A., Goldberg, T., and Goldman, D. (2002). A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am. J. Psychiatry 159, 652-654.
124. Manoach, D.S., Greve, D.N., Lindgren, K.A., and Dale, A.M. (2003). Identifying regional activity associated with temporally separated components of working memory using event-related functional MRI. Neuroimage 20, 1670-1684.
125. Martins Serra, A., Jones, S.H., Toone, B., and Gray, J.A. (2001). Impaired associative learning in chronic schizophrenics and their first-degree relatives: a study of latent inhibition and the Kamin blocking effect. Schizophr. Res. 48, 273-289.
126. McClure, M.M., Barch, D.M., Flory, J.D., Harvey, P.D., and Siever, L.J. (2008). Context processing in schizotypal personality disorder: evidence of specificity of impairment to the schizophrenia spectrum. J. Abnorm. Psychol. 117, 342-354.
127. McIntosh, A.M., Gow, A., Luciano, M., Davies, G., Liewald, D.C., Harris, S.E., Corley, J., Hall, J., Starr, J.M., Porteous, D.J., et al. (2013). Polygenic risk for schizophrenia is associated with cognitive change between childhood and old age. Biol. Psychiatry 73, 938-943.
128. Meisenzahl, E.M., Schmitt, G.J., Scheuerecker, J., and Moller, H.J. (2007). The role of dopamine for the pathophysiology of schizophrenia. Int. Rev. Psychiatry 19, 337-345.
129. Meltzer, H.Y., Park, S., and Kessler, R. (1999). Cognition, schizophrenia, and the atypical antipsychotic drugs. Proc. Natl. Acad. Sci. USA 96, 13591-13593.
130. Mesholam-Gately, R.I., Giuliano, A.J., Goff, K.P., Faraone, S.V., and Seidman, L.J. (2009). Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 23, 315-336.
131. Mikell, C.B., McKhann, G.M., Segal, S., McGovern, R.A., Wallenstein, M.B., and Moore, H. (2009). The hippocampus and nucleus accumbens as potential therapeutic targets for neurosurgical intervention in schizophrenia. Stereotact. Funct. Neurosurg. 87, 256-265.
132. Miller, D.D., Perry, P.J., Cadoret, R.J., and Andreasen, N.C. (1994). Clozapine's effect on negative symptoms in treatment-refractory schizophrenics. Compr. Psychiatry 35, 8-15.
133. Milstein, J.A., Dalley, J.W., and Robbins, T.W. (2005). Neuropharmacology of Attention. In L. Itti, G. Rees and J.K. Tsotsos (Eds.), Neurobiology of Attention. e-publication (New York, NY: Elsevier Inc./Academic Press). pp. 57-62.
134. Monteleone, P., Di Lieto, A., Martiadis, V., Bartoli, L., and Maj, M. (2002). Correlations between negative symptoms and peripheral G protein levels in mononuclear leukocytes of deficit and nondeficit schizophrenics. Preliminary results. Eur. Arch. Psychiatry Clin. Neurosci. 252, 214-218.
135. Morris, S.E., Heerey, E.A., Gold, J.M., and Holroyd, C.B. (2008). Learning-related changes in brain activity following errors and performance feedback in schizophrenia. Schizophr. Res. 99, 274-285.
136. Morris, R.W., Vercammen, A., Lenroot, R., Moore, L., Langton, J.M., Short, B., Kulkarni, J., Curtis, J., O'Donnell, M., Weickert, C.S., et al. (2012). Disambiguating ventral striatum fMRI-related BOLD signal during reward prediction in schizophrenia. Mol. Psychiatry 17, 235, 280-239.
137. Morris, R., Griffiths, O., Le Pelley, M.E., and Weickert, T.W. (2013). Attention to irrelevant cues is related to positive symptoms in schizophrenia. Schizophr. Bull. 39, 575-582.
138. Moser, P.C., Hitchcock, J.M., Lister, S., and Moran, P.M. (2000). The pharmacology of latent inhibition as an animal model of schizophrenia. Brain Res. Brain Res. Rev. 33, 275-307.
139. Moustafa, A.A. and Gluck, M.A. (2011). Computational cognitive models of prefrontal-striatal-hippocampal interactions in Parkinson's disease an schizophrenia. Neural. Netw. 24, 575-591.
140. Murray, G.K., Cheng, F., Clark, L., Barnett, J.H., Blackwell, A.D., Fletcher, P.C., Robbins, T.W., Bullmore, E.T., and Jones, P.B. (2008). Reinforcement and reversal learning in first-episode psychosis. Schizophr. Bull. 34, 848-855.
141. Mushquash, A.R., Fawcett, J.M., and Klein, R.M. (2012). Inhibition of return and schizophrenia: a meta-analysis. Schizophr. Res. 135, 55-61.
142. Myers, C.E., Shohamy, D., Gluck, M.A., Grossman, S., Kluger, A., Ferris, S., Golomb, J., Schnirman, G., and Schwartz, R. (2003). Dissociating hippocampal versus basal ganglia contributions to learning and transfer. J. Cogn. Neurosci. 15, 185-193.
143. Myers, C.E., Hopkins, R.O., DeLuca, J., Moore, N.B., Wolansky, L.J., Sumner, J.M., Golomb, J., Schnirman, G., and Schwartz, R. (2008). Learning and generalization deficits in patients with memory impairments due to anterior communicating artery aneurysm rupture or hypoxic brain injury. Neuropsychology 22, 681-686.
144. Neuhaus, A.H., Karl, C., Hahn, E., Trempler, N.R., Opgen-Rhein, C., Urbanek, C., Hahn, C., Ta, T.M., and Dettling, M. (2011). Dissection of early bottom-up and top-down deficits during visual attention in schizophrenia. Clin. Neurophysiol. 122, 90-98.
145. Nielsen, M.O., Rostrup, E., Wulff, S., Bak, N., Broberg, B.V., Lublin, H., Kapur, S., and Glenthoj, B. (2012). Improvement of brain reward abnormalities by antipsychotic monotherapy in schizophrenia. Arch. Gen. Psychiatry 69, 1195-1204.
146. Noudoost, B. and Moore, T. (2011). The role of neuromodulators in selective attention. Trends Cogn. Sci. 15, 585-591.
147. Okubo, Y., Suhara, T., Suzuki, K., Kobayashi, K., Inoue, O., Terasaki, O., Someya, Y., Sassa, T., Sudo, Y., and Matsushima, E., et al. (1997). Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385, 634-636.
148. Olabi, B., Ellison-Wright, I., McIntosh, A.M., Wood, S.J., Bullmore, E., and Lawrie, S.M. (2011). Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies. Biol. Psychiatry 70, 88-96.
149. Paquet, F., Soucy, J.P., Stip, E., Levesque, M., Elie, A., and Bedard, M.A. (2004). Comparison between olanzapine and haloperidol on procedural learning and the relationship with striatal D2 receptor occupancy in schizophrenia. J. Neuropsychiatry Clin. Neurosci. 16, 47-56.
150. Perry, W., Heaton, R.K., Potterat, E., Roebuck, T., Minassian, A., and Braff, D.L. (2001). Working memory in schizophrenia: transient "online" storage versus executive functioning. Schizophr. Bull. 27, 157-176.
151. Pessiglione, M., Seymour, B., Flandin, G., Dolan, R.J., and Frith, C.D. (2006). Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans. Nature 442, 1042-1045.
152. Polgar, P., Farkas, M., Nagy, O., Kelemen, O., Rethelyi, J., Bitter, I., Myers, C.E., Gluck, M.A., and Kéri, S. (2008). How to find the way out from four rooms? The learning of "chaining" associations may shed light on the neuropsychology of the deficit syndrome of schizophrenia. Schizophr. Res. 99, 200-207.
153. Polgar, P., Rethelyi, J.M., Balint, S., Komlosi, S., Czobor, P., and Bitter, I. (2010). Executive function in deficit schizophrenia: what do the dimensions of the Wisconsin Card Sorting Test tell us? Schizophr. Res. 122, 85-93.
154. Preuschoff, K., Bossaerts, P., and Quartz, S.R. (2006). Neural differentiation of expected reward and risk in human subcortical structures. Neuron 51, 381-390.
155. Purdon, S.E., Woodward, N., Lindborg, S.R., and Stip, E. (2003). Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol. Psychopharmacology (Berl) 169, 390-397.
156. Rascle, C., Mazas, O., Vaiva, G., Tournant, M., Raybois, O., Goudemand, M., and Thomas, P. (2001). Clinical features of latent inhibition in schizophrenia. Schizophr. Res. 51, 149-161.
157. Reichenberg, A. (2010). The assessment of neuropsychological functioning in schizophrenia. Dialogues Clin. Neurosci. 12, 383-392.
158. Risch, S.C. (1996). Pathophysiology of schizophrenia and the role of newer antipsychotics. Pharmacotherapy 16(1 Pt 2), 11-14.
159. Rosenheck, R., Cramer, J., Xu, W., Thomas, J., Henderson, W., Frisman, L., Fye, C., and Charney, D. (1997). A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N. Engl. J. Med. 337, 809-815.
160. Rossi, A., Daneluzzo, E., Tomassini, A., Struglia, F., Cavallaro, R., Smeraldi, E., and Stratta, P. (2006). The effect of verbalization strategy on Wisconsin Card Sorting Test performance in schizophrenic patients receiving classical or atypical antipsychotics. BMC Psychiatry 6, 3.
161. Rueter, L.E., Ballard, M.E., Gallagher, K.B., Basso, A.M., Curzon, P., and Kohlhaas, K.L. (2004). Chronic low dose risperidone and clozapine alleviate positive but not negative symptoms in the rat neonatal ventral hippocampal lesion model of schizophrenia. Psychopharmacology (Berl) 176, 312-319.
162. Sapir, A., Dobrusin, M., Ben-Bashat, G., and Henik, A. (2007). Neuroleptics reverse attentional effects in schizophrenia patients. Neuropsychologia 45, 3263-3271.
163. Scherer, H., Stip, E., Paquet, F., and Bedard, M.A. (2003). Mild procedural learning disturbances in neuroleptic-naive patients with schizophrenia. J. Neuropsychiatry Clin. Neurosci. 15, 58-63.
164. Scherer, H., Bedard, M.A., Stip, E., Paquet, F., Richer, F., Beriault, M., Rodriguez, J.P., and Motard, J.P. (2004). Procedural learning in schizophrenia can reflect the pharmacologic properties of the antipsychotic treatments. Cogn. Behav. Neurol. 17, 32-40.
165. Schmajuk, N.A. (2001). Hippocampal dysfunction in schizophrenia. Hippocampus 11, 599-613.
166. Schmajuk, N.A., Christiansen, B., and Cox, L. (2000). Haloperidol reinstates latent inhibition impaired by hippocampal lesions: data and theory. Behav. Neurosci. 114, 659-670.
167. Schmidt-Hansen, M., Killcross, A.S., and Honey, R.C. (2009). Latent inhibition, learned irrelevance, and schizotypy: assessing their relationship. Cogn. Neuropsychiatry 14, 11-29.
168. Schneider, K.K., Schote, A.B., Meyer, J., and Frings, C. (2015). Genes of the dopaminergic system selectively modulate top-down but not bottom-up attention. Cogn. Affect. Behav. Neurosci. 15, 104-116.
169. Schooler, N.R. (1994). Negative symptoms in schizophrenia: assessment of the effect of risperidone. J. Clin. Psychiatry 55(Suppl.), 22-28.
170. Schultz, W., Dayan, P., and Montague, P.R. (1997). A neural substrate of prediction and reward. Science 275, 1593-1599.
171. Schwartz, M., Wiggins, O., Naudin, J., and Spitzer, M. (2005). Rebuilding reality: a phenomenology of aspects of chronic schizophrenia. Phenomenol. Cognit. Sci. 4, 91-115.
172. Seeman, P. and Ulpian, C. (1983). Neuroleptics have identical potencies in human brain limbic and putamen regions. Eur. J. Pharmacol. 94, 145-148.
173. Sereno, A.B. and Holzman, P.S. (1996). Spatial selective attention in schizophrenic, affective disorder, and normal subjects. Schizophr. Res. 20, 33-50.
174. Serper, M.R. and Chou, J.C.Y. (1997). Novel neuroleptics improve attentional functioning in schizophrenic patients: ziprasidone and aripiprazole. CNS Spectrums 2, 56-59.
175. Shirazi-Southall, S., Rodriguez, D.E., and Nomikos, G.G. (2002). Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 26, 583-594.
176. Shohamy, D., Myers, C.E., Kalanithi, J., and Gluck, M.A. (2008). Basal ganglia and dopamine contributions to probabilistic category learning. Neurosci. Biobehav. Rev. 32, 219-236.
177. Shohamy, D., Mihalakos, P., Chin, R., Thomas, B., Wagner, A.D., and Tamminga, C. (2009). Learning and generalization in schizophrenia: effects of disease and antipsychotic drug treatment. Biol. Psychiatry 67, 926-932.
178. Silverstein, S.M., Spaulding, W.D., Menditto, A.A., Savitz, A., Liberman, R.P., Berten, S., and Starobin, H. (2009). Attention shaping: a reward-based learning method to enhance skills training outcomes in schizophrenia. Schizophr. Bull. 35, 222-232.
179. Smith, E.E., Eich, T.S., Cebenoyan, D., and Malapani, C. (2011). Intact and impaired cognitive-control processes in schizophrenia. Schizophr. Res. 126, 132-137.
180. Snyder, P.J., Jackson, C.E., Piskulic, D., Olver, J., Norman, T., and Maruff, P. (2008). Spatial working memory and problem solving in schizophrenia: the effect of symptom stabilization with atypical antipsychotic medication. Psychiatry Res. 160, 316-326.
181. Somlai, Z., Moustafa, A.A., Keri, S., Myers, C.E., and Gluck, M.A. (2011). General functioning predicts reward and punishment learning in schizophrenia. Schizophr. Res. 127, 131-136.
182. Spencer, K.M., Nestor, P.G., Valdman, O., Niznikiewicz, M.A., Shenton, M.E., and McCarley, R.W. (2011). Enhanced facilitation of spatial attention in schizophrenia. Neuropsychology 25, 76-85.
183. Stephan, K.E., Penny, W.D., Daunizeau, J., Moran, R.J., and Friston, K. (2009). Bayesian model selection for group studies. Neuroimage 46, 1004-1017.
184. Stip, E. (2006). [Cognition, schizophrenia and the effect of antipsychotics]. Encephale 32(3 Pt 1), 341-350.
185. Swerdlow, N.R., Braff, D.L., Hartston, H., Perry, W., and Geyer, M.A. (1996). Latent inhibition in schizophrenia. Schizophr. Res. 20, 91-103.
186. Tamminga, C.A., Stan, A.D., and Wagner, A.D. (2010). The hippocampal formation in schizophrenia. Am. J. Psychiatry. 167, 1178-1193.
187. Tamrakar, S.M., Nepal, M.K., Koirala, N.R., Sharma, V.D., Gurung, C.K., and Adhikari, S.R. (2006). An open, randomized, comparative study of efficacy and safety of risperidone and haloperidol in schizophrenia. Kathmandu Univ. Med. J. 4, 152-160.
188. Tu, P.C., Yang, T.H., Kuo, W.J., Hsieh, J.C., and Su, T.P. (2006). Neural correlates of antisaccade deficits in schizophrenia, an fMRI study. J. Psychiatr. Res. 40, 606-612.
189. Van Snellenberg, J.X., Torres, I.J., and Thornton, A.E. (2006). Functional neuroimaging of working memory in schizophrenia: task performance as a moderating variable. Neuropsychology 20, 497-510.
190. van Veelen, N.M., Vink, M., Ramsey, N.F., and Kahn, R.S. (2010). Left dorsolateral prefrontal cortex dysfunction in medication-naive schizophrenia. Schizophr. Res. 123, 22-29.
191. Vita, A., De Peri, L., Deste, G., and Sacchetti, E. (2012). Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies. Transl. Psychiatry 2, e190.
192. Waltz, J.A., Frank, M.J., Robinson, B.M., and Gold, J.M. (2007). Selective reinforcement learning deficits in schizophrenia support predictions from computational models of striatal-cortical dysfunction. Biol. Psychiatry 62, 756-764.
193. Waltz, J.A., Frank, M.J., Wiecki, T.V., and Gold, J.M. (2011). Altered probabilistic learning and response biases in schizophrenia: behavioral evidence and neurocomputational modeling. Neuropsychology 25, 86-97.
194. Wasserman, J.I., Barry, R.J., Bradford, L., Delva, N.J., and Beninger, R.J. (2012). Probabilistic classification and gambling in patients with schizophrenia receiving medication: comparison of risperidone, olanzapine, clozapine and typical antipsychotics. Psychopharmacology (Berl) 222, 173-183.
195. Weickert, T.W. and Goldberg, T.E. (2005). First-and second-generation antipsychotic medication and cognitive processing in schizophrenia. Curr. Psychiatry Rep. 7, 304-310.
196. Weickert, T.W., Terrazas, A., Bigelow, L.B., Malley, J.D., Hyde, T., Egan, M.F., Weinberger, D.R., and Goldberg, T.E. (2002). Habit and skill learning in schizophrenia: evidence of normal striatal processing with abnormal cortical input. Learn. Mem. 9, 430-442.
197. Weickert, T.W., Goldberg, T.E., Egan, M.F., Apud, J.A., Meeter, M., Myers, C.E., Gluck, M.A., and Weinberger, D.R. (2010). Relative risk of probabilistic category learning deficits in patients with schizophrenia and their siblings. Biol. Psychiatry 67, 948-955.
198. Weickert, T.W., Leslie, F., Rushby, J.A., Hodges, J.R., and Hornberger, M. (2013a). Probabilistic association learning in frontotemporal dementia and schizophrenia. Cortex 49, 101-106.
199. Weickert, T.W., Mattay, V.S., Das, S., Bigelow, L.B., Apud, J.A., Egan, M.F., Weinberger, D.R., and Goldberg, T.E. (2013b). Dopaminergic therapy removal differentially effects learning in schizophrenia and Parkinson's disease. Schizophr. Res. 149, 162-166.
200. Weinberger, D.R. (1999). Cell biology of the hippocampal formation in schizophrenia. Biol. Psychiatry 45, 395-402.
201. Wiesel, F.A., Farde, L., Nordstrom, A.L., and Sedvall, G. (1990). Central D1-and D2-receptor occupancy during antipsychotic drug treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 14, 759-767.
202. Williams, J.H., Wellman, N.A., Geaney, D.P., Cowen, P.J., Feldon, J., and Rawlins, J.N. (1998). Reduced latent inhibition in people with schizophrenia: an effect of psychosis or of its treatment. Br. J. Psychiatry 172, 243-249.
203. Woodward, N.D., Purdon, S.E., Meltzer, H.Y., and Zald, D.H. (2005). A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 8, 457-472.
204. Zierhut, K., Bogerts, B., Schott, B., Fenker, D., Walter, M., Albrecht, D., Steiner, J., Schütze, H., Northoff, G., Düzel, E., et al. (2010). The role of hippocampus dysfunction in deficient memory encoding and positive symptoms in schizophrenia. Psychiatry Res. 183, 187-194.